Myeloproliferation

Everyone knows the importance of blood to the human body. When suffering from blood diseases, it will have a great impact on the patient's health. Myeloblastic trilineage hyperplasia is a disease that is relatively harmful to the human body. When the disease is discovered, it must be treated in time. Myeloblastic trilineage hyperplasia will not only affect the patient's life and health, but also threaten the patient's life safety when the disease is serious.

Hazard 1

The clinical manifestations are nonspecific. MDS usually has a slow onset, but in a few cases it has an acute onset. Generally, the rate of transformation to leukemia is more than 50% within one year from the onset of the disease. 90% of patients suffer from anemia. These include pale complexion, fatigue, palpitations after activity, and shortness of breath. Anemia in the elderly often aggravates existing chronic heart and lung diseases. Fever accounts for 50%, of which fever of unknown cause accounts for 10% to 15%, manifested as recurrent infection and fever, with the respiratory tract, perianal area and urinary system being the most common sites of infection.

Hazard 2

Severe granulocytosis can reduce the patient's resistance. Bleeding accounts for 20%, which is common in the respiratory tract, digestive tract, and also intracranial hemorrhage. The early bleeding symptoms are mild, mostly skin and mucous membrane bleeding, gum bleeding or epistaxis. Female patients may have excessive menstruation. The bleeding trend worsens in the late stage, and cerebral hemorrhage becomes one of the main causes of death in patients.

Hazard Three

Most patients with myelodysplasia experience dizziness, fatigue, upper abdominal discomfort, and bone and joint pain. Most cases present with anemia, which lasts for months to years. About 20% to 60% of cases have a bleeding tendency during the course of the disease, which varies in severity and petechiae appear on the skin. Bleeding gums and nosebleeds. In severe cases, there may be gastrointestinal or cerebral hemorrhage. About half of the patients had fever during the course of the disease. The fever was related to infection and the fever type was uncertain. Respiratory tract infection was the most common, and the rest had sepsis, perianal and perineal infections.

Hazard 4

The harm of myelodysplastic syndrome to people is manifested in many aspects. Nearly 50% of MDS patients with combined myelofibrosis have mild to moderate reticular fiber increase in the bone marrow, among which 10% to 15% of patients have obvious fibrosis. There is another rare condition called acute myelodysplasia with myelofibrosis. Patients have acute onset and have symptoms and physical signs such as anemia, bleeding, and infection.

Hazard 5

It is important to know the main harmful manifestations of myelodysplastic syndrome as early as possible so as to provide timely treatment. There is no hepatosplenomegaly, pancytopenia in the peripheral blood, mild changes in the morphology of mature red blood cells, only a few broken red blood cells, occasional primitive cells, immature granulocytes or nucleated red blood cells, enlarged hematopoietic tissue area in bone marrow tissue sections, abnormal development of the three lineage hematopoietic cells, and obvious fibrosis. Death from bone marrow failure or transformation to leukemia often occurs within a few months.

Hazard 6

Patients with myelodysplasia will have enlarged liver, spleen and lymph nodes: patients do not have enlarged liver and spleen at the onset of the disease, but as the disease progresses, about 10%-60% of patients have mild enlargement of the liver; about 60% are accompanied by mild enlargement of the spleen. Severe enlargement of the liver and spleen is rarely seen.